Study #2023-0408
A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-186 (also known as MVC-101), an EGFR x CD3 Conditional Bispecific Redirected Activation (COBRA) protein in patients with unresectable locally advanced or metastatic cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
TAK-186
Description
The main aim of this study is to check for side effects and tolerability of TAK-186 (also known as MVC-101) in adults with unremovable advanced or metastatic cancer. Another aim is to characterize and evaluate the activity of TAK-186 (MVC-101). Participants may receive treatment throughout the study for a maximum of 13 months and will be followed up at 30 days and 90 days and then every 12 weeks for up to 48 weeks after the last treatment.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study phase:
Physician name:
George Blumenschein
Department:
Thoracic/Head & Neck Medical Oncology
For general questions about clinical trials:
1-844-794-1615
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.